Expressing support for the designation of May 17, 2026, as "DIPG Awareness Day" to raise awareness and encourage research into cures for diffuse intrinsic pontine glioma (DIPG) and pediatric cancers in general.

Overview

H.R.1295, introduced in the 119th Congress, is a non-binding resolution expressing support for designating May 17, 2026, as “DIPG Awareness Day.” The resolution aims to raise awareness of diffuse intrinsic pontine glioma (DIPG) and pediatric cancers, encourage research funding and efforts, and highlight the need for better care for affected children and families.

Main purpose and intent

• Officially designate May 17, 2026, as DIPG Awareness Day.
• Promote public awareness about DIPG and pediatric brain cancer.
• Encourage increased and improved funding for pediatric cancer research.
• Advocate for expanded research to understand DIPG, develop effective treatments, and provide comprehensive care to patients and families.
• Encourage consideration of mortality rates and life-years lost when evaluating grant applications and research funding priorities.

Key provisions and changes

• Formal designation: The House expresses support for naming a specific day (May 17, 2026) as DIPG Awareness Day.
• Awareness and education: Urges the public to become more informed about DIPG and the challenges in securing sufficient pediatric cancer research funding.
• Research emphasis: Supports expanded research aimed at better understanding DIPG, developing treatments, and improving comprehensive care for affected children and their families.
• Funding considerations: Encourages public and private sources of research funding to place greater emphasis on mortality rates and life-years lost as significant factors in grant review processes.

Who or what is affected

• DIPG patients and their families: Indirectly affected through advocacy for better care and treatment options.
• Pediatric cancer research funding: Encouraged to prioritize DIPG and life-years lost as factors in funding decisions.
• Public awareness: Seeks to broaden understanding of DIPG among the general population.
• Federal and private research communities: Motivated to expand and/or adjust research initiatives and resource allocation.

Procedural and timeline aspects

• Status: Referred to the House Committee on Energy and Commerce after introduction.
• Sponsorship: Primary sponsors are Rep. Debbie Dingell, with co-sponsors Reps. Michael McCaul and Dave Joyce.
• No binding policy changes or funding authorizations; this is a commemorative, expressional resolution intended to recognize and promote awareness and research emphasis.

Potential impact

• Increased visibility for DIPG and pediatric cancer research within the legislative branch and among the public.
• Could influence future funding discussions by highlighting DIPG mortality and life-years lost as relevant factors in grant-making decisions.
• Serves as a platform for advocates to push for more robust federal and private support for DIPG and pediatric oncology research.